Iovance Biotherapeutics
IOVA
IOVA
85 hedge funds and large institutions have $429M invested in Iovance Biotherapeutics in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0.69% more ownership
Funds ownership: 76.4% → 77.09% (+0.69%)
30% less call options, than puts
Call options by funds: $178K | Put options by funds: $254K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
85
Holding in Top 10
2
Calls
$178K
Puts
$254K
Top Buyers
| 1 | +$23.6M | |
| 2 | +$14.2M | |
| 3 | +$12.8M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.59M |
| 5 |
JPMorgan Chase & Co
New York
|
+$5.45M |
Top Sellers
| 1 | -$12.4M | |
| 2 | -$8.03M | |
| 3 | -$4.04M | |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$848K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$524K |